Handelsavisen
prelaunch
Companies Healthcare 199730.KQ
19
199730.KQ KOSDAQ Pharmaceuticals

199730.Kq

$3 040,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
7,18 %
Op margin
-27,1 %
ROE
-55,4 %
Net margin
-39,4 %
Debt / equity
0,72
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.

Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-55,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 199730.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 199730.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.72, indicating a moderate reliance on debt financing. However, its liquidity position is weak, with a current ratio of 0.69, suggesting that the company may struggle to meet its short-term obligations. The company's cash and equivalents amount to 2,144,235,820 KRW, which is significantly lower than its long-term debt of 11,857,493,720 KRW, resulting in a negative net cash position.

    Profitability metrics reveal a challenging financial situation. The company reported a net loss of 9,131,042,240 KRW, with a return on equity of -55.37% and a return on assets of -26.12%. These figures are well below the industry norms for profitability, indicating that the company is underperforming relative to its peers in terms of generating returns for shareholders and utilizing its assets efficiently.

    The company's revenue is not segmented by product or geographic region in the available data, making it difficult to assess the concentration of its revenue streams. However, the lack of detailed segment reporting suggests that the company may be heavily reliant on a few key products or markets, which could pose a risk to its financial stability if those areas experience downturns.

    Looking ahead, the company's growth trajectory is uncertain. The absence of specific outlook data for the current and next fiscal years means that there is no clear indication of expected revenue changes or operational improvements. The company's negative operating and net income, combined with negative operating and free cash flows, suggest that it is currently in a contractionary phase and may require significant operational or strategic changes to return to growth.

    The company faces several risk factors, including its weak liquidity position and the potential for dilution. The risk assessment indicates a medium level of liquidity risk, primarily due to the company's inability to cover its short-term liabilities with its current assets. While the risk of dilution is currently low, the company's negative net cash position and high debt levels could necessitate future equity issuances, which would dilute existing shareholders.

    Recent events and filings do not provide specific details about the company's operations or financial strategy. The lack of recent transcripts or detailed filings suggests that the company may not be actively communicating its strategic direction or financial performance to the public, which could limit investor confidence and market visibility.

    Key takeaways
    • The company is experiencing significant financial distress, as evidenced by its negative net income and return on equity.
    • The company's liquidity position is weak, with a current ratio below 1 and a negative net cash position.
    • The company's profitability metrics are well below industry norms, indicating poor performance relative to its peers.
    • The company's growth trajectory is uncertain, with no clear indication of expected revenue changes or operational improvements.
    • The company faces medium liquidity risk and potential dilution if it needs to raise additional capital.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $3 040,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $16.49B
    Net cash
    -$9.71B
    Current ratio
    0.7
    Debt / equity
    0.7
    ROA
    -26.1%
    ROE
    -55.4%
    Cash conversion
    16.0%
    CapEx / revenue
    -6.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-27,1 %Bottom quartile
    Net Margin-39,5 %Bottom quartile
    ROE-55,4 %Bottom quartile
    Capex / Rev-6,6 %Below median
    D/E0,72Bottom quartile
    Cash Conv0,16Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 199730.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    199730.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage